% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • efficient_frontier2002 efficient_frontier2002 Aug 24, 2010 4:03 PM Flag

    News -- STA-9090 in Combination with Docetaxel

    From the above link: "Used to treat breast, lung, prostate, stomach and head/neck cancers, docetaxel generates roughly $2 billion/year for Sanofi-Aventis."

    ($2 billion is 17 times SNTA's market cap, BTW.)

    From SNTA's 8/24/10 press release:
    “The combination of STA-9090 and docetaxel could possibly expand the therapeutic potential of both agents.”

    I'm not close to being a biotech expert, but it sounds like SNTA's HSP-9090 may not only save Sanofi-Aventis's docetaxel from going off-patent in a few years, but more importantly, create a much improved combination drug.

    Of course this is just one of many opportunities for STA-9090 -- doktorr_demento's recent 5-star post discusses many more.

    Comments are welcome.

0.343+0.072(+26.61%)Jul 22 3:59 PMEDT